- Cetuximab, sold
under the
brand name
Erbitux, is an
epidermal growth factor receptor (EGFR)
inhibitor medication used for the
treatment of metastatic...
- ImClone's
stock price dropped sharply at the end of 2001 when its drug
Erbitux, an
experimental monoclonal antibody,
failed to get the
expected Food and...
- in 2010. At ImClone,
Waksal led the
company to
develop the
cancer drug
Erbitux (cetuximab).
During the
course of its
review process with the Food and...
-
headquarters from Geneva,
Switzerland to Darmstadt.
Drugs they
market include Erbitux, UFT, Rebif, Mavenclad, Novantrone, Gonal, Ovidrel/Ovitrelle, Zorbtive...
- ImClone's
stock price dropped sharply at the end of 2001 when its drug
Erbitux, an
experimental monoclonal antibody,
failed to get the
expected Food and...
-
predictive of a very poor
response to
panitumumab (Vectibix) and
cetuximab (
Erbitux)
therapy in
colorectal cancer. As of 2008, the most
reliable way to predict...
-
antibody (
Erbitux) were
attributed to IgE
directed against α-Gal
containing N-glycans on this antibody. The
incidencies of
anaphylaxis due to
Erbitux were...
-
neurology and immunology. In oncology, its
first marketed product is
Erbitux (cetuximab), for
which it has
marketing rights worldwide,
apart from North...
-
European medicines Agency (June 2014). “
Erbitux®
Summary of
Product Characteristics (PDF).“ 2015-11-19. “Cetuximab (
Erbitux).
About the
Center of Drug Evaluation...
- in
royalties annually on
marketed drugs including Copaxone, Rebif, and
Erbitux. As of 2015, the
Weizmann Institute had
approximately 2,500 students, postdoctoral...
